Ask AI
ProCE Banner Activity

Decera: 前景、隐忧与方向:血液生物标志物在阿尔茨海默病护理中的全球视角

Clinical Thought

来自世界各地的阿兹海默病专家就血液生物标志物发表了见解,内容涉及这些生物标志物在世界不同地区初步进入临床实践的情况,以及未来在各级医疗系统诊断路径中可能的位置。

Released: June 05, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by an educational grant from Lilly.

Lilly

Target Audience

This activity is intended for global primary care physicians, general practitioners, general neurologists, nurse practitioners, physician associates, and other healthcare professionals caring for patients at risk of developing Alzheimer’s Disease.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Decera: 应用基于证据的策略和生物标志物检测临床指导,来指导阿兹海默护理全程中的临床决策与转诊。

Disclosure

Primary Author

Atsushi Iwata, MD, PhD: consultant/advisor/speaker: Biogen, Eisai, Fujirebio, Janssen, Kowa, Lilly, MSD, Otsuka, Sony, Sysmex, UCB.

Sebastian Palmqvist, MD, PhD: consultant/advisor/speaker: BioArctic, Danaher, Eisai, Lilly, Novo Nordisk, Roche, Sanofi.

Jiong Shi, MD, PhD, FAAN, has no relevant financial relationships to disclose.

Raymond Scott Turner, PhD, MD, FANA, FAAN: researcher (paid to institution): Cognition Therapeutics, Eisai, Lilly; consultant/advisor/speaker: Lilly.